Crystalline TLR-8 Modulator Solid Forms
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for potent and selective modulators of Toll-like receptor 8 (TLR-8) with reduced off-target liabilities to effectively treat various diseases involving autoimmunity, inflammation, and viral infections, as existing modulators may have unwanted side effects.
Innovation Solution
The development of crystalline forms of (R)-2-((2-amino-7-fluoropyrido[3,2-d]pyrimidin-4-yl)amino)-2-methylhexan-1-ol gentisic acid, hippuric acid, and succinic acid, characterized by specific X-ray powder diffraction patterns, which serve as novel modulators of TLR-8, potentially offering improved therapeutic efficacy with minimized off-target effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing TLR-8 modulators are used to stimulate immune response, then therapeutic benefit is achieved, but off-target liabilities and unwanted side effects occur
Solution Approach 1:
The patent applies parameter changes by developing new chemical compounds with modified molecular structures (diamino pyrido[3,2-d]pyrimidine core with specific substituents) to achieve selective TLR-8 modulation. The structural parameters including R1-R6 groups, X1-X6 linkers, and Y1-Y6 substituents are optimized to enhance TLR-8 binding affinity while reducing off-target interactions, thereby improving therapeutic reliability without increasing harmful effects
Solution Approach 2:
The patent implements local quality by introducing specific functional groups and structural features at particular positions on the pyrido[3,2-d]pyrimidine core. The differentiated substitution patterns at R1-R6 positions and the specific configurations of X1-X6 and Y1-Y6 groups create localized interaction zones that selectively engage TLR-8 receptors, enabling potent immune stimulation with minimized off-target liabilities
2Productivity
If TLR-8 activation is enhanced to treat viral infections and autoimmune diseases, then immune response is improved, but selectivity and reduced side effects become challenging
Solution Approach 1:
The patent applies segmentation by dividing the TLR-8 modulator into distinct functional modules: the pyrido[3,2-d]pyrimidine core structure, R1-R6 substituent groups, X1-X6 linker regions, and Y1-Y6 terminal groups. Each segment contributes specific binding interactions with TLR-8, allowing the molecule to achieve high affinity and selectivity through modular assembly, thereby enhancing immune response while maintaining molecular selectivity
Solution Approach 2:
The patent implements composite materials by creating hybrid molecular structures that combine the pyrido[3,2-d]pyrimidine scaffold with diverse substituent combinations. The composite nature of these compounds, integrating multiple functional groups and structural elements, enables simultaneous optimization of TLR-8 binding affinity, selectivity, and pharmacological properties, achieving enhanced immune response with reduced complexity challenges
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These crystalline forms provide effective modulation of TLR-8, enhancing immune responses and treating conditions like hepatitis B, HIV, and other immune-related disorders with reduced off-target liabilities, thereby improving treatment outcomes.
Implementation Method 1
characterized by an X-ray powder diffraction (XRPD) pattern comprising three or more peaks at 4.4°, 8.7°, 12.9°, 14.9°, 17.3°, 19.5°, 24.8°, 25.7°, or 26.3° 2θ (± 0.2° 2θ), Compound I gentisic acid
Data Source
Figure 1
Figure 2~3
Figure 4~5
AI summary
The present disclosure provides solid forms, solvates and hydrates of (R)-2-((2- amino-7-fluoropyrido[3,2-d]pyrimidin-4-yl)amino)-2-methylhexan-l-ol, and methods of making.